02:46 PM EDT, 03/18/2025 (MT Newswires) -- Aditxt ( ADTX ) shares were up over 57% in recent Tuesday trading after its acquisition target, Appili Therapeutics, submitted four new federal funding proposals totaling $117.5 million.

The largest funding proposal seeks $46.3 million to develop a vaccine against invasive fungal infections from the National Institute of Allergy and Infectious Diseases, Appili said.

Aditxt ( ADTX ) subsidiary, Adivir, is in the process of acquiring Appili, with the transaction expected to close in Q1, the company said.

Trading volume stood at over 87 million shares against a daily average of about 376,000.

Price: 6.90, Change: +2.53, Percent Change: +57.89